Literature DB >> 14728985

State-of-the-art 2003 on PKU gene therapy.

Zhaobing Ding1, Cary O Harding, Beat Thöny.   

Abstract

Phenylketonuria (or PKU) is a well-known and widespread genetic disease for which many countries perform newborn screening, and life-long dietary restriction is still the ultimate and effective therapy. However, the diet is complicated, unpalatable, and expensive. The long-term effects of diet discontinuation in adults, except for the serious adverse effects of maternal hyperphenylalaninemia upon the developing fetus, have not been systematically studied, but cognitive decline and neurologic abnormalities have been anecdotally reported. Thus, alternative approaches for PKU therapy, including gene therapy, must be further explored. Here we summarize past present nonviral and viral gene transfer approaches, both in vitro studies and preclinical animal trials, to delivering the PAH gene into liver or other organs as potential alternatives to life-long phenylalanine-restricted dietary therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14728985      PMCID: PMC2706831          DOI: 10.1016/j.ymgme.2003.09.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  49 in total

Review 1.  Gene therapy progress and prospects: nonviral vectors.

Authors:  T Niidome; L Huang
Journal:  Gene Ther       Date:  2002-12       Impact factor: 5.250

Review 2.  Intracellular barriers to non-viral gene transfer.

Authors:  Delphine Lechardeur; Gergely L Lukacs
Journal:  Curr Gene Ther       Date:  2002-05       Impact factor: 4.391

3.  Fate of DNA targeted to hepatocytes by asialoglycoprotein polylysine conjugates.

Authors:  G W Wu; J R Chowdhury; V R Bommineni; S K Basu; C H Wu; N R Chowdhury
Journal:  Proc Assoc Am Physicians       Date:  1995-07

Review 4.  Gene therapy as an alternative to liver transplantation.

Authors:  Betsy T Kren; Namita Roy Chowdhury; Jayanta Roy Chowdhury; Clifford J Steer
Journal:  Liver Transpl       Date:  2002-12       Impact factor: 5.799

Review 5.  Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects.

Authors:  G Werner-Felmayer; G Golderer; E R Werner
Journal:  Curr Drug Metab       Date:  2002-04       Impact factor: 3.731

6.  Effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring.

Authors:  S Cho; J D McDonald
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

Review 7.  National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

8.  Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria.

Authors:  Rikke Christensen; Flemming Güttler; Thomas G Jensen
Journal:  Mol Genet Metab       Date:  2002-08       Impact factor: 4.797

Review 9.  Gene therapy with viral vectors.

Authors:  Neeltje A Kootstra; Inder M Verma
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

10.  The phenylketonuria mouse model: a meeting review.

Authors:  J David McDonald; Maria Andriolo; Francesco Calì; Mario Mirisola; Stefano Puglisi-Allegra; Valentino Romano; Christineh N Sarkissian; Carolyn B Smith
Journal:  Mol Genet Metab       Date:  2002-08       Impact factor: 4.797

View more
  10 in total

Review 1.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

Review 2.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

3.  Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.

Authors:  Kelly Hamman; Heather Clark; Eugenio Montini; Muhsen Al-Dhalimy; Markus Grompe; Milton Finegold; Cary O Harding
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

4.  Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

Authors:  C O Harding; M B Gillingham; K Hamman; H Clark; E Goebel-Daghighi; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

Review 5.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

6.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

Review 7.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

Review 8.  Progress toward cell-directed therapy for phenylketonuria.

Authors:  Co Harding
Journal:  Clin Genet       Date:  2008-05-21       Impact factor: 4.438

9.  Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.

Authors:  Alexandre Rebuffat; Cary O Harding; Zhaobing Ding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 10.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.